TheraVet SA (ALVET.PA)
EUR 0.08
(0.0%)
EUR 0.08
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -530.79 Thousand EUR | -138.24% |
| 2022 | -992.8 Thousand EUR | -64.49% |
| 2021 | -603.55 Thousand EUR | -437.91% |
| 2020 | -112.2 Thousand EUR | -23187.45% |
| 2019 | 486.00 EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -152.07 Thousand EUR | 0.0% |
| 2024 Q1 | -152.07 Thousand EUR | 11.5% |
| 2023 Q2 | -566.78 Thousand EUR | -505.77% |
| 2023 Q1 | -93.56 Thousand EUR | 93.68% |
| 2023 Q4 | -171.83 Thousand EUR | 0.0% |
| 2023 Q3 | -171.83 Thousand EUR | 69.68% |
| 2023 FY | -2.36 Million EUR | -138.24% |
| 2022 Q1 | -279.03 Thousand EUR | -333.52% |
| 2022 Q3 | -217.36 Thousand EUR | 84.02% |
| 2022 Q4 | -1.47 Million EUR | -580.67% |
| 2022 FY | -992.8 Thousand EUR | -64.49% |
| 2022 Q2 | -1.36 Million EUR | -387.48% |
| 2021 Q1 | -205.47 Thousand EUR | -166.11% |
| 2021 Q3 | -96.3 Thousand EUR | 94.86% |
| 2021 Q2 | -1.87 Million EUR | -811.52% |
| 2021 FY | -603.55 Thousand EUR | -437.91% |
| 2021 Q4 | 119.49 Thousand EUR | 224.08% |
| 2020 Q4 | 310.8 Thousand EUR | 1189.13% |
| 2020 Q3 | -28.53 Thousand EUR | -120.88% |
| 2020 Q2 | 136.7 Thousand EUR | 595.9% |
| 2020 FY | -112.2 Thousand EUR | -23187.45% |
| 2020 Q1 | -27.56 Thousand EUR | 0.0% |
| 2019 FY | 486.00 EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | 185.889% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 113.561% |
| Adocia SA | 1.38 Million EUR | 138.325% |
| Aelis Farma SA | 12.35 Million EUR | 104.295% |
| Biophytis S.A. | -803 Thousand EUR | 33.898% |
| Advicenne S.A. | 1.42 Million EUR | 137.223% |
| genOway Société anonyme | 20.1 Million EUR | 102.641% |
| IntegraGen SA | 5.01 Million EUR | 110.577% |
| Medesis Pharma S.A. | -2.66 Million EUR | 80.081% |
| Neovacs S.A. | 29.31 Thousand EUR | 1910.725% |
| NFL Biosciences SA | -56.06 Thousand EUR | -846.768% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 124.655% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 62.601% |
| Sensorion SA | 3.78 Million EUR | 114.013% |
| Theranexus Société Anonyme | -4.63 Million EUR | 88.557% |
| TME Pharma N.V. | -127 Thousand EUR | -317.95% |
| Valbiotis SA | 2.66 Million EUR | 119.895% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | 141.894% |
| DBV Technologies S.A. | 4.15 Million EUR | 112.761% |
| Genfit S.A. | 28.22 Million EUR | 101.881% |
| GeNeuro SA | -293.8 Thousand EUR | -80.666% |
| Innate Pharma S.A. | -4.12 Million EUR | 87.12% |
| Inventiva S.A. | 17.5 Million EUR | 103.033% |
| MaaT Pharma SA | 1.65 Million EUR | 132.072% |
| MedinCell S.A. | 9.28 Million EUR | 105.715% |
| Nanobiotix S.A. | 36.2 Million EUR | 101.466% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 123.835% |
| Poxel S.A. | 1000.00 EUR | 53179.6% |
| GenSight Biologics S.A. | 3 Million EUR | 117.693% |
| Transgene SA | -28.4 Million EUR | 98.131% |
| Valneva SE | 52.83 Million EUR | 101.005% |